Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Zepzelca (lurbinectedin)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Boryung Group, Jazz, Luye Group, PharmaMar

Drug class:

Alkylating agent, Apoptosis stimulant, RNA polymerase inhibitor

Related drugs:

‹

›

SLFN11 overexpression	Small Cell Lung Cancer	SLFN11 overexpression	Small Cell Lung Cancer	lurbinectedin Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) lurbinectedin Sensitive : D AACR 2023 - 2wk	lurbinectedin Sensitive: D – Preclinical AACR 2023 - 2 weeks lurbinectedin Sensitive : D AACR 2023 - 2 weeks - (New D)
POU2F3 overexpression	Small Cell Lung Cancer	POU2F3 overexpression	Small Cell Lung Cancer	lurbinectedin Sensitive: D – Preclinical AACR 2023 - 2 weeks (New D) lurbinectedin Sensitive : D AACR 2023 - 2wk	lurbinectedin Sensitive: D – Preclinical AACR 2023 - 2 weeks lurbinectedin Sensitive : D AACR 2023 - 2 weeks - (New D)
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	lurbinectedin Sensitive: A2 - Guideline lurbinectedin Sensitive : A2	lurbinectedin Sensitive: A2 - Guideline lurbinectedin Sensitive : A2
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2
SLFN11 underexpression	Small Cell Lung Cancer	SLFN11 underexpression	Small Cell Lung Cancer	M6620 + lurbinectedin Sensitive: D – Preclinical M6620 + lurbinectedin Sensitive : D	M6620 + lurbinectedin Sensitive: D – Preclinical M6620 + lurbinectedin Sensitive : D
SLFN11 underexpression	Small Cell Lung Cancer	SLFN11 underexpression	Small Cell Lung Cancer	AZD6738 + lurbinectedin Sensitive: D – Preclinical AZD6738 + lurbinectedin Sensitive : D	AZD6738 + lurbinectedin Sensitive: D – Preclinical AZD6738 + lurbinectedin Sensitive : D